Intravitreal dexamethasone in diabetic macular oedema (DMO) - enhancing the response to anti-VEGF in non- or poor responders
3 February 2023
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Aflibercept, Anti-VEGF, Dexamethasone implant, Diabetic macular oedema, Persistent, Ranibizumab, Resistant
This study aimed to describe the outcomes of a switch back from DEXi (dexamethasone implant) to anti-VEGF therapy in eyes that were treated temporarily with DEXi after an initial poor response to anti VEGF. Twenty-three eyes of 17 patients were...
Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents
2 August 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Aflibercept, Anti-vascular endothelial growth factor, Bevacizumab, Endophthalmitis, Filling, Prefilled syringe, Ranibizumab, Syringe
In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...
